⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11451566 | 0.97 | LMNA (0.53) | — | |
| SCHEMBL22309883 | 0.82 | SLC22A6 (0.61) | — | |
| SCHEMBL11678561 | 0.80 | TSHR (0.63) | — | |
| SCHEMBL4801627 | 0.80 | TSHR (0.63) | — | |
| SCHEMBL14332654 | 0.80 | TSHR (0.63) | — | |
| Succinic Acid SCHEMBL2110249 | 0.80 | LMNA (0.64) | — | |
| Succinic Acid SCHEMBL6699563 | 0.76 | LMNA (0.69) | — | |
| SCHEMBL8638108 | 0.75 | — | — | |
| Succinic Acid SCHEMBL21867134 | 0.75 | LMNA (1.00) | — | |
| Succinic Acid SCHEMBL24696 | 0.75 | LMNA (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216099-A1 | SYSTEMS AND METHODS FOR BACTERIA-SPECIFIC PRO-PHOTOSENSITIZERS TO POTENTIATE BACTERICIDE | THE GENERAL HOSPITAL CORPORATION (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024216099-A1 | SYSTEMS AND METHODS FOR BACTERIA-SPECIFIC PRO-PHOTOSENSITIZERS TO POTENTIATE BACTERICIDE | THE GENERAL HOSPITAL CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-118103077-A | System and method for producing hyperpolarized material | 预视成像科技有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117529341-A | System and method for producing hyperpolarized material | 预视成像科技有限责任公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117500802-A | LACTIVICIN compounds, their preparation and their use as antibacterial agents | 费多拉制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-9233163-B2 | Hydrolytically releasable prodrugs for sustained release nanoparticle formulations | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2016-01-12 | — | — | US | disclosed |
| US-8778645-B2 | Method for the production of glutaconate | BASF SE (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20130296285-A1 | Design of Hydrolytically Releasable Prodrugs for Sustained Release Nanoparticle Formulations | THE CHILDRENS HOSPITAL OF PHILADELPHIA (US) | 2013-11-07 | — | — | US | disclosed |
| CN-101133023-A | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA SA (FR) | 2008-02-27 | — | — | CN | disclosed |
| US-20030204873-A1 | Method for producing transgenic plants with modified 5-aminolevulinic acid biosynthesis, and method for identifying 5-aminolevulinic acid synthesis effectors | AVENTIS CROPSCIENCE GMBH (DE) | 2003-10-30 | — | — | US | disclosed |
| US-6603062-B1 | Introducing into monocotyledons nucleic acid molecules encoding a enzyme isolated from purple bacteria; | AVENTIS CROPSCIENCE GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-0239620-A4 | PRODUCTION OF AMINO ACIDS USING COUPLED AMINOTRANSFERASES. | GENETICS INST (US) | 1989-11-14 | — | — | EP | disclosed |
| EP-0239620-A1 | PRODUCTION OF AMINO ACIDS USING COUPLED AMINOTRANSFERASES | GENETICS INSTITUTE, INC. (US) | 1987-10-07 | — | — | EP | disclosed |
| WO-1987001727-A1 | PRODUCTION OF AMINO ACIDS USING COUPLED AMINOTRANSFERASES | GENETICS INSTITUTE, INC. (US) | 1987-03-26 | — | — | WO | disclosed |